Farther Finance Advisors LLC Acquires 725 Shares of Cencora, Inc. (NYSE:COR)

Farther Finance Advisors LLC raised its position in shares of Cencora, Inc. (NYSE:CORFree Report) by 45.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,305 shares of the company’s stock after acquiring an additional 725 shares during the period. Farther Finance Advisors LLC’s holdings in Cencora were worth $518,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of COR. Swedbank AB increased its position in Cencora by 2.3% during the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after acquiring an additional 31,104 shares during the last quarter. United Bank increased its position in Cencora by 4.2% during the third quarter. United Bank now owns 5,601 shares of the company’s stock valued at $1,261,000 after acquiring an additional 225 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in Cencora by 2.0% during the third quarter. Oppenheimer & Co. Inc. now owns 5,850 shares of the company’s stock valued at $1,317,000 after acquiring an additional 115 shares during the last quarter. CIBC Asset Management Inc increased its position in Cencora by 6.6% during the third quarter. CIBC Asset Management Inc now owns 39,237 shares of the company’s stock valued at $8,825,000 after acquiring an additional 2,438 shares during the last quarter. Finally, Empirical Finance LLC increased its position in Cencora by 2.1% during the third quarter. Empirical Finance LLC now owns 5,499 shares of the company’s stock valued at $1,238,000 after acquiring an additional 114 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,648 shares of company stock worth $3,382,462. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

Shares of Cencora stock opened at $258.09 on Monday. The company has a market capitalization of $50.05 billion, a PE ratio of 36.71, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a 50-day simple moving average of $247.59 and a two-hundred day simple moving average of $239.15. Cencora, Inc. has a one year low of $214.77 and a one year high of $263.70.

Cencora (NYSE:CORGet Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.85%. Cencora’s dividend payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.20.

Check Out Our Latest Analysis on Cencora

Cencora Profile

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Read More

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.